[{"id":"9d91719c-a4f8-489a-a4f8-f503e0f382e7","acronym":"PBL-0405-01","url":"https://clinicaltrials.gov/study/NCT06273852","created_at":"2024-02-23T16:26:42.227Z","updated_at":"2024-07-02T16:35:03.110Z","phase":"Phase 1","brief_title":"A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors","source_id_and_acronym":"NCT06273852 - PBL-0405-01","lead_sponsor":"Pure Biologics S.A.","biomarkers":" ROR1 • TNFA • CASP3 • GZMB • CD86","pipe":"","alterations":" ","tags":["ROR1 • TNFA • CASP3 • GZMB • CD86"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 04/29/2024","start_date":" 04/29/2024","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-05-17"},{"id":"7a9ea525-1684-4896-a1a4-8cd8fac90402","acronym":"Lyell START","url":"https://clinicaltrials.gov/study/NCT05891197","created_at":"2023-06-06T14:07:07.777Z","updated_at":"2024-07-02T16:35:16.712Z","phase":"","brief_title":"A Biomarker Screening Protocol for Participants With Solid Tumors","source_id_and_acronym":"NCT05891197 - Lyell START","lead_sponsor":"Lyell Immunopharma, Inc.","biomarkers":" ROR1","pipe":"","alterations":" ","tags":["ROR1"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 05/19/2023","start_date":" 05/19/2023","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-03-01"},{"id":"8a5250ad-f3b6-42f8-b24b-850d6478ad00","acronym":"","url":"https://clinicaltrials.gov/study/NCT05274451","created_at":"2022-03-10T13:52:49.005Z","updated_at":"2024-07-02T16:35:16.777Z","phase":"Phase 1","brief_title":"A Study to Investigate LYL797 in Adults With Solid Tumors","source_id_and_acronym":"NCT05274451","lead_sponsor":"Lyell Immunopharma, Inc.","biomarkers":" ROR1","pipe":"","alterations":" ","tags":["ROR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LYL797"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 03/29/2022","start_date":" 03/29/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-03-01"},{"id":"b150f7b0-fa0a-4051-89d4-8cd9aed4ac61","acronym":"NVG111-101","url":"https://clinicaltrials.gov/study/NCT04763083","created_at":"2021-02-21T13:52:27.874Z","updated_at":"2024-07-02T16:35:43.724Z","phase":"Phase 1","brief_title":"First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies","source_id_and_acronym":"NCT04763083 - NVG111-101","lead_sponsor":"NovalGen Ltd.","biomarkers":" ROR1","pipe":"","alterations":" ","tags":["ROR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NVG-111"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 05/14/2021","start_date":" 05/14/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-07-07"},{"id":"9873bcb1-fd60-4087-b95d-ec821e1febef","acronym":"","url":"https://clinicaltrials.gov/study/NCT05748938","created_at":"2023-03-01T15:02:00.643Z","updated_at":"2024-07-02T16:35:54.515Z","phase":"Phase 1/2","brief_title":"A Study of RD14-01 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05748938","lead_sponsor":"920th Hospital of Joint Logistics Support Force of People's Liberation Army of China","biomarkers":" ROR1","pipe":"","alterations":" ","tags":["ROR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RD14-01"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 02/08/2023","start_date":" 02/08/2023","primary_txt":" Primary completion: 08/08/2024","primary_completion_date":" 08/08/2024","study_txt":" Completion: 02/08/2025","study_completion_date":" 02/08/2025","last_update_posted":"2023-03-01"},{"id":"5b3bda45-2924-46c8-b0d5-e8e77501cf44","acronym":"","url":"https://clinicaltrials.gov/study/NCT05638828","created_at":"2022-12-06T15:58:00.768Z","updated_at":"2024-07-02T16:35:59.606Z","phase":"Phase 1","brief_title":"A Study of RD14-01 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05638828","lead_sponsor":"Shen Lin","biomarkers":" ROR1","pipe":"","alterations":" ","tags":["ROR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RD14-01"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/01/2022","start_date":" 12/01/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-12-06"},{"id":"8ac1e017-da1c-4007-8416-53084f3ac3fb","acronym":"CIRLL study","url":"https://clinicaltrials.gov/study/NCT03420183","created_at":"2021-01-18T16:52:25.006Z","updated_at":"2024-07-02T16:37:02.627Z","phase":"Phase 1b","brief_title":"A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies","source_id_and_acronym":"NCT03420183 - CIRLL study","lead_sponsor":"Oncternal Therapeutics, Inc","biomarkers":" ROR1","pipe":"","alterations":" ","tags":["ROR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • zilovertamab (UC-961)"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 02/13/2018","start_date":" 02/13/2018","primary_txt":" Primary completion: 04/01/2019","primary_completion_date":" 04/01/2019","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2019-02-20"},{"id":"f88b6d43-708c-4d24-806a-442e945a2f4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01358604","created_at":"2021-01-18T05:33:31.070Z","updated_at":"2024-07-02T16:37:32.757Z","phase":"","brief_title":"Biomarkers in Samples From Young Patients With Neuroblastoma","source_id_and_acronym":"NCT01358604","lead_sponsor":"Children's Oncology Group","biomarkers":" MYC • MYCN • ROR1","pipe":" | ","alterations":" MYCN amplification • ROR1 expression","tags":["MYC • MYCN • ROR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification • ROR1 expression"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 05/01/2011","start_date":" 05/01/2011","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2016-04-15"}]